SCHEMBL10070536

SCHEMBL10070536

Cc1ncccc1OC(=O)N1CCC(c2nc(-c3cccc(F)c3)n[nH]2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPT1A P50416 2/20 0.46
KIT P10721 4/20 0.41
AKT1 P31749 3/20 0.41
AKT2 P31751 3/20 0.41
P2RY12 Q9H244 1/20 0.40
HSD11B1 P28845 1/20 0.39
TLR9 Q9NR96 2/20 0.39
TLR8 Q9NR97 2/20 0.39
TLR7 Q9NYK1 2/20 0.39
XPO1 O14980 1/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
HTR2B P41595 1/20 0.37
CPT2 P23786 1/20 0.37
CPT1B Q92523 1/20 0.37
HPGDS O60760 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10070550 0.93 CPT1A (0.40) CPT1AKITAKT1AKT2P2RY12
SCHEMBL10070076 0.91 KIT (0.44) KITAKT1AKT2P2RY12HSD11B1
SCHEMBL10069714 0.90 HSD11B1 (0.43) KITP2RY12HSD11B1TLR9TLR8
SCHEMBL10070106 0.90 CPT1A (0.46) CPT1AKITAKT1AKT2P2RY12
SCHEMBL10070539 0.89 P2RY12 (0.47) P2RY12HSD11B1HCRTR1HCRTR2HTR2B
SCHEMBL10070095 0.89 CPT2 (0.49) CPT1AP2RY12HSD11B1HCRTR1HCRTR2
SCHEMBL10069718 0.89 CPT1A (0.45) CPT1AKITAKT1AKT2P2RY12
SCHEMBL10070556 0.88 HCRTR1 (0.42) CPT1AAKT1AKT2HCRTR1HCRTR2
SCHEMBL10070107 0.88 AKT1 (0.42) CPT1AAKT1AKT2HCRTR1HCRTR2
SCHEMBL10070552 0.85 HTR2B (0.43) AKT1P2RY12HSD11B1TLR9TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207199-B2 Azole compound ASTELLAS PHARMA INC. (JP) 2012-06-26 US disclosed
US-20110118311-A1 AZOLE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-05-19 US disclosed
WO-2010007966-A1 AZOLE COMPOUND アステラス製薬株式会社 (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118311-A1 AZOLE COMPOUND FAAH, FAAH2, TRPV1 CPT1A 1233/4885KIT 681/4885AKT1 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.